Perhaps I should have emphasized the word cure in #msg-61679544 :) I really cannot guess what will be the FDA' position regarding early filing, but I do expect good 24-week SVR data from that trial and even see a reasonable chance for monotherapy to work in GT2/3 patients.
VRUS added a 8-week GT2/GT3 treatment arm to the ELECTRON study using the 400mg dose. If all treatable patients in this study achieve an RVR at 4 weeks, which was previously demonstrated in PROTON, and an SVR at 8 weeks this would reduce the time patients need to be on interferon by 16 weeks (current SOC for GT2/GT3 patients is 24 weeks of Peg/Riba). An advancement of this magnitude deserves to be brought to market early if PSI-7977 continues to prove safe and tolerable across all studies come November.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.